Nemesio Villa-Ruano,Maricruz Anaya-Ruiz,Luis Villafaña-Diaz et al.
Nemesio Villa-Ruano et al.
Repurposing of approved drugs in a new strategy to combat cancer that leads to savings in time and investment. Atovaquone is a US FDA-approved drug for treatment of Pneumocystis carinii pneumonia and malaria. Patent US2023017373 describe th...
Patent landscape of platelet growth factor receptor and c-KIT targets [0.03%]
血小板衍生生长因子受体和c-Kit靶标的专利布局分析
Hai-Long Zhang,Qian Kong
Hai-Long Zhang
Type III receptor tyrosine kinase, e.g., PDGFR, are associated with various autoimmune diseases. To show the status of PDGFR and c-KIT targets, we performed the US patent analysis. The present study showed that the R&D of c-KIT target was m...
Morita-Baylis-Hillman adducts and their derivatives: a patent-based exploration of diverse biological activities [0.03%]
基于专利的莫里塔-贝利斯-希尔曼加合物及其衍生物多样生物活性探究
Ricardo S Porto,Viviane A Porto
Ricardo S Porto
Morita-Baylis-Hillman adducts are polyfunctionalized compounds that result from a three-component reaction involving an electrophilic sp2 carbon (aldehyde, ketone or imine) and the α-position of an activated alkene, catalyzed by a tertiary...
Therapeutic charisma of imidazo [2,1-b] [1,3,4]-thiadiazole analogues: a patent review [0.03%]
咪唑并[2,1-b][1,3,4]噻二唑类似物的治疗魅力：专利回顾
Anuradha Mehra,Rekha Sangwan,Aryan Mehra et al.
Anuradha Mehra et al.
Imidazothiadiazole was discovered around the 1950s era, containing an imidazole ring fused to a thiadiazole ring. Imidazothiadiazole exhibit versatile pharmacological properties including anticonvulsant, cardiotonic, anti-inflammatory, diur...
Irene von der Weid,Cristina d&#x;Urso de Souza Mendes,Paula C Fonseca et al.
Irene von der Weid et al.
Mpox disease was reported in 110 countries since May 2022, with 88,026 cases and 148 deaths by 21 June 2023. Although some drugs were already approved for Mpox treatment, the available smallpox vaccines can provide 85% cross-prevention, but...
Hai-Long Zhang,Qian Kong
Hai-Long Zhang
RET and ROS1 are becoming key targets for targeted therapy. To show current landscape of ROS1 and RET targets, a patent analysis was performed. The present results indicated that inhibitor structures of ROS1 target demonstrated unique eleme...
Contact lens disinfectants against Acanthamoeba keratitis: an overview of recent patents and future needs [0.03%]
阿卡纳达amoeba角膜炎的隐形眼镜消毒剂：最近专利和未来需求概述
Ruqaiyyah Siddiqui,Naveed A Khan
Ruqaiyyah Siddiqui
Hermann Am Mucke
Hermann Am Mucke
A snapshot of recent noteworthy developments in the patent literature of relevance to pharmaceutical and medical research and development.
Patent analysis of novel therapeutic approaches for treating Alzheimer's disease 2018-2023 [0.03%]
2018-2023年阿尔茨海默病新疗法专利分析
Faiza Saleem,Fouzia Naz,Khalid M Khan
Faiza Saleem
Daniel Hilton,Vicki Allen,Graham Lewis
Daniel Hilton